We are Sorry, This Page doesn't Exist

SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled Elevage Study of azeliragon in patients with mild Alzheimer&#.....»»

Amgen Inc. said Wednesday data from phase 1 studies of an investigational bispecific T cell engager (BiTE) molecules, updated with investigational AMG 420 results for the treatment .....»»

- Announced updated clinical data from Phase 2 basket study of setmelanotide in MC4R pathway heterozygous (HET) obesity, demonstrating consistent weight and hunger responses in patients with high-i.....»»

Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients. Alnylam Ph.....»»

Akcea and Ionis Pharmaceuticals shares made a solid gain on Monday after the companies announced positive top-line data for a midstage trial in patients with established cardiovascular disease and........»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data. read more.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Eli Lilly's treatment reduced a harmful substance in the brains of patients with Alzheimer's disease and slowed their rate of cognitive decline. Patients sit inside the Alzheimer's Foundation in Mexico City Thomson Reuters Eli Lilly's.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Shares of Biogen Inc. gained 5.6% in trading on Monday after another drugmaker shared positive clinical data about an experimental Alzheimer's disease treatment that is similar to a Biogen therapy under review by the Food and Drug A.....»»

A Triangle drugmaker that's seen positive results with its Covid-19 treatment internationally can now start treating patients in the U.S. Raleigh's RedHill Biopharma (Nasdaq: RDHL) has received approval from the U.S. Food and Drug Administration .....»»

Amgen Inc on Thursday reported better-than-expected first-quarter results and said it plans to study psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the new coronavirus......»»

Amgen Inc on Thursday reported better-than-expected first-quarter results on Thursday and said it plans to study psoriasis drug Otezla as a potential treatment for COVID-19, the respiratory disease caused by the new coronavirus......»»

Gainers Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares climbed 138.2% to $5.74 after the company reported that its new data from study of 6 critically-ill coronavirus patients showed 100% survival following treatment with its CAP-1002. read more.....»»

A key U.S. government trial of Gilead Sciences Inc's experimental coronavirus treatment may yield results as early as mid-May, according to the study's lead investigator, after doctors clamored to enroll their patients in the study......»»

Temple University Hospital said Wednesday it has started the first clinical trial in the United States testing an experimental therapy known as gimsilumab as a potential coronavirus treatment. Gimsilumab, a type of drug known as a fully human monoclonal.....»»